Shah, Ami N. http://orcid.org/0000-0003-1347-3782
Carroll, Kristen J.
Gerratana, Lorenzo
Lin, Chenyu
Davis, Andrew A.
Zhang, Qiang
Jacob, Saya
Finkelman, Brian
Zhang, Youbin
Qiang, Wenen
D’Amico, Paolo
Reduzzi, Carolina
Gradishar, William J.
Behdad, Amir
Cristofanilli, Massimo
Funding for this research was provided by:
Lynn Sage Cancer Research Foundation
Article History
Received: 5 January 2021
Accepted: 17 April 2021
First Online: 2 June 2021
Declarations
:
: Ami N. Shah: Honorarium—Taiho, Daiichi-Sankyo, Pfizer; Advisory Board—d AbbVie; Lorenzo Gerratana: Advisory board—Lilly; Amir Behdad: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus); Author; Pfizer, Bayer, Foundation Medicine; Massimo Cristofanilli: Advisory Board—G1 Therapeutics, Cytodyn, Sermonix, LIlly, Foundation Medicine. Fees for Non-CME Services Received Directly from Commercial Interest or their Agents—Pfizer. Contracted Research—G1 Therapeutics. Others: none.
: This protocol was approved by the institutional review board at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (STU00203283 and STU00214133).
: Patients provided written consent to participate in part 1.
: Requirement for informed consent was waived for part 2 for this retrospective review of de-identified patient data.